Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479037
Status:
COMPLETED
Last Update Posted:
2012-05-08
First Post:
2007-05-23
Brief Title:
Effect of Full Length Parathyroid Hormone PTH1-84 or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis FP-006-IM
Sponsor:
Nycomed
Organization:
Nycomed
Study Overview
Official Title:
A 24-week International Multi Centre Randomised Open Label Parallel Group Phase IV Clinical Trial Investigating Changes in Bone Formation Markers in Postmenopausal Women With Primary Osteoporosis Treated With Either PTH1-84 or Strontium Ranelate
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this trial is to show that PTH1-84 is superior to strontium ranelate in bone formation measured as changes in bone formation markers over a treatment period of 24 weeks in postmenopausal women with primary osteoporosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-006065-16 | None | None | None |